Acromegaly and bone.

Minerva Endocrinol

Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.

Published: June 2018

Growth hormone (GH) and insulin-like growth factor-I (IGF-I) have pleiotropic effects on the skeleton throughout the lifespan by influencing bone formation and resorption. Despite these positive effects on skeletal metabolism, in presence of GH and IGF-I excess, bone turnover increases excessively leading to deterioration of bone microarchitecture and high risk of fragility fractures, thereby impairing quality of life. Coexistent hypogonadism, diabetes mellitus, hypovitaminosis D, hyperparathyroidism, and over-replacement with glucocorticoids impair bone framework, however, the effects of acromegaly on bone mineral density (BMD) are still controversial and despite normalization of bone turnover after treatment, the risk for fractures remains increased. As a matter of fact, a major clinical aspect emerging from the studies published so far is the lack of clinical-diagnostic tools able to reliably predict the appearance of fractures in patients with acromegaly occurring even in the presence of normal or low-normal BMD. New radiological software and clinical devices have been employed in acromegaly patients highlighting a significant impairment of both cortical and cancellous bone. In this article, we summarize the pathophysiology, clinical aspects and the new diagnostic tools to better understand bone impairment in acromegaly.

Download full-text PDF

Source
http://dx.doi.org/10.23736/S0391-1977.17.02733-XDOI Listing

Publication Analysis

Top Keywords

acromegaly bone
8
bone
8
bone turnover
8
acromegaly
5
bone growth
4
growth hormone
4
hormone insulin-like
4
insulin-like growth
4
growth factor-i
4
factor-i igf-i
4

Similar Publications

Sclerostin and OPG/RANK-L system take part in bone remodeling in patients with acromegaly.

Front Endocrinol (Lausanne)

January 2025

Department and Clinic of Endocrinology, Diabetes and Isotope Therapy, Wroclaw Medical University, Wrocław, Poland.

Article Synopsis
  • Acromegaly is marked by increased bone turnover and higher vertebral fracture risk, with sclerostin inhibiting bone formation and playing a role in the OPG/RANK-L system that regulates bone metabolism.
  • The study investigated levels of sclerostin, osteoprotegerin (OPG), and RANK-L in 126 patients with varying acromegaly activity, aiming to explore connections between sclerostin and bone health.
  • Results showed lower sclerostin levels in acromegaly patients compared to controls, with notable differences in OPG levels across groups but no significant changes in RANK-L; a positive correlation was found between sclerostin and OPG in patients with various acromegaly
View Article and Find Full Text PDF

Association of trabecular bone score corrected for tissue thickness with glucose metabolism in acromegaly.

Front Endocrinol (Lausanne)

December 2024

5th Department of Internal Medicine, Comenius University Faculty of Medicine, University Hospital Bratislava, Bratislava, Slovakia.

Introduction: Acromegaly is associated with increased vertebral fracture (VF) risk regardless of bone mineral density (BMD). However, the vertebral trabecular compartment is still low; a possible contributor to this may be impaired glucose metabolism (GM) which frequently complicates acromegaly. Additionally, soft tissue thickness may confound bone imaging in acromegaly patients.

View Article and Find Full Text PDF

Acromegaly and gigantism are rare diseases, usually caused by a growth hormone-secreting pituitary adenoma, recently renamed GH-secreting pituitary neuroendocrine tumor (GH-PitNET). The transsphenoidal approach is the mainstay of treatment, although a non-negligible number of patients require a multimodal approach with neo-adjuvant or adjuvant medical and radiation therapy. Understanding the clinical complexity of acromegaly and gigantism is essential to improve treatment safety and success.

View Article and Find Full Text PDF

Novel approach to bone comorbidity in resistant acromegaly.

Pituitary

December 2024

Institute of Endocrine and Metabolic Sciences, Università Vita-Salute San Raffaele, Via Olgettina, 58, Milan, 20132, Italy.

Article Synopsis
  • Active acromegaly can cause serious, irreversible complications like osteopathy and fragile fractures, which are linked to longer disease duration and high growth hormone levels.
  • Unlike primary osteoporosis, bone mineral density isn't a good predictor for fracture risk in acromegaly patients, as they often have normal or only slightly reduced bone mass, but compromised bone quality.
  • The manuscript aims to review evidence on skeletal fragility in patients with active and resistant acromegaly, highlighting the need for disease control and potential protective effects from vitamin D and pasireotide therapies.
View Article and Find Full Text PDF

Introduction: The purpose of this study was to evaluate the impact of disease activity and gonadal status on bone mineral density (BMD) and turnover markers (BTMs) in individuals with acromegaly.

Materials And Methods: Subjects underwent laboratory tests for PTH, 25-hydroxyvitamin D, calcium, phosphorus, osteocalcin (OC) and C-telopeptide (CTX-1) and bone densitometry at the lumbar spine (LS), femoral neck (FN) and total hip (TH).

Results: Sixty participants (48.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!